山东大学耳鼻喉眼学报 ›› 2021, Vol. 35 ›› Issue (3): 81-86.doi: 10.6040/j.issn.1673-3770.0.2020.016

• 临床研究 • 上一篇    下一篇

鼻咽癌患者miR-429、miR-200C表达与预后关系分析

王中卫,杨林,郭亚,孙斌,王亚利,马秀龙,任宏涛,包兴   

  1. 西安交通大学第二附属医院 放疗科, 陕西 西安 710004
  • 发布日期:2021-05-14
  • 通讯作者: 王中卫. E-mail:wangzhongwei601@163.com

Analysis of the relationship between miR-429 and miR-200C expression and prognosis in patients with nasopharyngeal carcinoma

WANG Zhongwei, YANG Lin, GUO Ya, SUN Bin, WANG Yali, MA Xiulong, REN Hongtao, BAO Xing   

  1. Department of Radiation Therapy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, Shaanxi, China
  • Published:2021-05-14

PDF (PC)

158

摘要： 目的 探讨鼻咽癌患者miR-429、miR-200C表达与预后关系。 方法 选择2016年1月至2017年5月接受治疗的初治鼻咽癌患者80例,对病理穿刺组织样本行qRT-PCR检测对miR-429、miR-200C相抵表达量进行分析,治疗3个月后进行疗效评价。出院后以电话及门诊复诊的方式进行随访,记录患者生存时间。 结果 不同病理分期、T分期、N分期及临床分期患者miR-429及miR-200C相对表达量差异均具有统计学意义,且均随严重程度的增加表达量下降(P<0.05)。治疗3个月后80例患者总体有效率为100%,其中CR 71例(88.75%),PR 9例(11.25%)。死亡及复发或转移的55例为预后不良组,无瘤生存的18例为预后良好组,预后良好组患者miR-429及miR-200C相对表达量均高于预后不良组(P<0.05)。miR-429相对表达量对鼻咽癌预后不良预测cut-off值为1.36,AUC为0.723,95%CI为0.547~0.898,灵敏度为82.15%,特异度为81.72%;miR-200C相对表达量对鼻咽癌预后不良预测cut-off值为0.53,AUC为0.713,95%CI为0.562~0.865,灵敏度为82.01%,特异度为79.61%。miR-429高表达组(miR-429相对表达量≥1.36)平均生存时间为(39.07±1.59)个月,95%CI:35.95~42.19;miR-429低表达组(miR-429相对表达量<1.36)平均生存时间为(23.57±1.02)个月,95%CI:21.57~25.58(P<0.05)。miR-200C高表达组(miR-200C相对表达量≥0.53)平均生存时间为(38.28±1.71)个月,95%CI:34.94~41.63;miR-200C低表达组(miR-200C相对表达量<0.53)平均生存时间为(23.52±1.07)个月,95%CI:21.42~25.62(P<0.05)。 结论 不同病理分期、T分期、N分期及临床分期鼻咽癌患者miR-429、miR-200C相对表达量有差异,且随着病情严重程度的升高miR-429、miR-200C表达量下降,miR-429相对表达量<1.36、miR-200C相对表达量<0.53时鼻咽癌患者生存时间下降。

关键词: 鼻咽癌, miR-429, miR-200C, 预后, 生存分析

Abstract: Objective To investigate the relationship between the expression of miR-429, miR-200C and prognosis in patients with nasopharyngeal carcinoma. Methods 80 patients with nasopharyngeal carcinoma who received treatment between January 2016 and May 2017 were selected Tissue puncture samples were subjected to qRT-PCR detection to analyze the offset expression of miR-429 and miR-200C, and three treatments were performed. The Efficacy will be evaluated in the coming months. After discharge from the hospital, follow-up was conducted by telephone and outpatient follow-up, and the survival time of the patient was recorded. Results The relative expression levels of miR-429 and miR-200C in patients with different pathological stages, T stages, N stages and clinical stages were statistically significantly different, and the expression levels decreased with the increase of severity(P<0.05). After three months of treatment, the overall effective rate of 80 patients was 100%, of which 71 were CR(88.75%)and 9 were PR(11.25%). Fifty-five patients with death, recurrence or metastasis belonged to the poor prognosis group, and 18 patients with tumor-free survival belonged to the good prognosis group. The relative expression levels of miR-429 and miR-200C in the good prognosis group were higher than those in the poor prognosis group(P<0.05). The relative expression of miR-429 has a predictive cut-off value of 1.36 for the poor prognosis of nasopharyngeal carcinoma. The AUC was 0.723, 95% CI of 0.547 to 0.898, sensitivity of 82.15%, and the specificity was 81.72%; relative expression of miR-200C The predictive cut-off value of poor prognosis for nasopharyngeal carcinoma was 0.53, the AUC was 0.713, 95%CI was 0.562-0.865, the sensitivity was 82.01%, and the specificity was 79.61%. The average survival time of the miR-429 high expression group(miR-429 relative expression level ≥ 1.36)was 39.07±1.59 months, with a 95%CI: of 35.95-42.19; miR-429 in the low expression group(miR-429 relative expression level < 1.36). The average survival time was 23.57±1.02 months, with a 95%CI of 21.57-25.58(P<0.05). The average survival time of the miR-200C high expression group(miR-200C relative expression ≥0.53)was(38.28±1.71)months the 95%CI was 34.94-41.63; and the miR was-200C in the low expression group(miR-200C relative expression <0.53 )The average survival time was 23.52±1.07 months, 95%CI: 21.42-25.62(P<0.05). Conclusion The relative expression levels of miR-429 and miR-200C in nasopharyngeal carcinoma patients at different pathological stages, T stages, N stages and clinical stages were different, and the expression levels of miR-429 and miR-200C decreased as the severity of the disease increased. The survival time of nasopharyngeal carcinoma patients decreased when the relative expression of miR-429 was <1.36 and the relative expression of miR-200C was <0.53.

Key words: Nasopharyngeal carcinoma, miR-429, miR-200C, Prognosis, Survival analysis

中图分类号: 

  • R766.04
[1] Kang M, Zhou PT, Long JX, et al. A new staging system for nasopharyngeal carcinoma based on intensity-modulated radiation therapy(IMRT)[J]. Oncotarget, 2017, 8(55):94188-94196. doi:10.18632/oncotarget.21615.
[2] 凌伟, 林初阳, 胡婷, 等. 广东省居民饮用凉茶及煲汤与鼻咽癌发病关系的流行病学研究[J]. 现代肿瘤医学, 2019, 27(7): 1229-1233. doi:10.3969/j.issn.1672-4992.2019.07.033. LING Wei, LIN Chuyang, HU Ting, et al. Association between traditional Chinese herbal soup, tea and risk of nasopharyngeal carcinoma in Guangdong China[J]. J Mod Oncol, 2019, 27(7):1229-1233. doi:10.3969/j.issn.1672-4992.2019.07.033.
[3] Li YF, Ding JW, Liao LM, et al. Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma[J]. Mol Clin Oncol, 2017, 7(3):378-382. doi:10.3892/mco.2017.1318.
[4] Liu C, Li G, Yang NT, et al. miR-324-3p suppresses migration and invasion by targeting WNT2B in nasopharyngeal carcinoma[J]. Cancer Cell Int, 2017, 17:2. doi:10.1186/s12935-016-0372-8.
[5] Liu YJ, Tao ZZ, Qu JN, et al. Long non-coding RNA PCAT7 regulates ELF2 signaling through inhibition of miR-134-5p in nasopharyngeal carcinoma[J]. Biochem Biophys Res Commun, 2017, 491(2):374-381. doi:10.1016/j.bbrc.2017.07.093.
[6] Chen P, Guo XF, Zhang LM, et al. MiR-200c is a cMyc-activated miRNA that promotes nasopharyngeal carcinoma by downregulating PTEN[J]. Oncotarget, 2017, 8(3):5206-5218. doi:10.18632/oncotarget.14123.
[7] 林少俊, 潘建基, 韩露, 等. 美国癌症研究联合会第七版肿瘤分期对鼻咽癌放疗预后的影响[J]. 中华放射肿瘤学杂志, 2011, 20(6):458-461. doi:10.3760/cma.j.issn.1004-4221.2011.06.004. LIN Shaojun, PAN Jianji, HAN Lu, et al. The different impact of 7th ed AJCC cancer staging system on nasopharyngeal carcinoma treated with conventional radiotherapy and intensity-modulated radiotherapy[J]. Chin J Radiat Oncol, 2011, 20(6):458-461. doi:10.3760/cma.j.issn.1004-4221.2011.06.004.
[8] 中国鼻咽癌临床分期工作委员会. 2010鼻咽癌调强放疗靶区及剂量设计指引专家共识[J]. 中华放射肿瘤学杂志, 2011, 20(4):267-269. doi:10.3760/cma.j.issn.1004-4221.2011.04.001.
[9] 杨青廷, 熊文婧, 刘也, 等. 《2015年第一版NCCN头颈部肿瘤临床实践指南》关于鼻咽癌更新内容及要点解读[J]. 医院与医学, 2016, 4(2):65-68.
[10] Li HL, Li XL, Ge XL, et al. MiR-34b-3 and miR-449a inhibit malignant progression of nasopharyngeal carcinoma by targeting lactate dehydrogenase A[J]. Oncotarget, 2016, 7(34):54838-54851. doi:10.18632/oncotarget.10761.
[11] Fan HN, Shao M, Huang SH, et al. MiR-593 mediates curcumin-induced radiosensitization of nasopharyngeal carcinoma cells via MDR1[J]. Oncol Lett, 2016, 11(6):3729-3734. doi:10.3892/ol.2016.4438.
[12] Sun KY, Peng T, Chen Z, et al. Long non-coding RNA LOC100129148 functions as an oncogene in human nasopharyngeal carcinoma by targeting miR-539-5p[J]. Aging(Albany NY), 2017, 9(3):999-1011. doi:10.18632/aging.101205.
[13] Zou J, Liu L, Wang Q, et al. Downregulation of miR-429 contributes to the development of drug resistance in epithelial ovarian cancer by targeting ZEB1[J]. Am J Transl Res, 2017, 9(3):1357-1368.
[14] Han YT, Zhao Q, Zhou J, et al. miR-429 mediates tumor growth and metastasis in colorectal cancer[J]. Am J Cancer Res, 2017, 7(2):218-233.
[15] Zhu SH, He XC, Wang L. Correlation analysis of miR-200b, miR-200c, and miR-141 with liver metastases in colorectal cancer patients[J]. Eur Rev Med Pharmacol Sci, 2017, 21(10):2357-2363.
[16] Tian H, He ZK. miR-200c targets nuclear factor IA to suppress HBV replication and gene expression via repressing HBV Enhancer I activity[J]. Biomedecine Pharmacother, 2018, 99:774-780. doi:10.1016/j.biopha.2018.01.141.
[17] Wu D, Lu P, Mi X, et al. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85[J]. Arch Gynecol Obstet, 2018, 297(3):699-707. doi:10.1007/s00404-018-4649-0.
[18] 王国栋, 黄建涛, 吴洋, 等. miR-429对头颈部鳞状细胞癌增殖的影响[J]. 口腔颌面外科杂志, 2015, 25(3):185-189. doi:10.3969/j.issn.1005-4979.2015.03.005. WANG Guodong, HUANG Jiantao, WU Yang, et al. miR-429 inhibits cell growth of head and neck squamous cell carcinoma[J]. J Oral Maxillofac Surg, 2015, 25(3):185-189. doi:10.3969/j.issn.1005-4979.2015.03.005.
[19] Pieraccioli M, Imbastari F, Antonov A, et al. Activation of miR200 by c-Myb depends on ZEB1 expression and miR200 promoter methylation[J]. Cell Cycle, 2013, 12(14):2309-2320. doi:10.4161/cc.25405.
[20] 伍思培. MYC通过靶向抑制miR-200c调节鼻咽癌肿瘤细胞的干性及其化疗药物抗性[D]. 广州: 南方医科大学, 2013.
[1] 姜超,周炫辰,韩杰,岳志勇. IVc期下咽癌特征分析及列线图预后模型构建[J]. 山东大学耳鼻喉眼学报, 2022, 36(4): 49-54.
[2] 程瑶,张震,杨吉,冯成敏,邓启成,张西,赵锐,朱鑫,吴俊志,刘海,邓世山. CIP2A在下咽癌中的表达及临床意义[J]. 山东大学耳鼻喉眼学报, 2022, 36(2): 40-44.
[3] 华红利,李松，陶泽璋. 人工智能在鼻咽癌诊疗中的研究进展[J]. 山东大学耳鼻喉眼学报, 2022, 36(2): 113-119.
[4] 周宇翔,,苗北平,卢永田. 首诊鼻咽癌内镜手术的治疗进展[J]. 山东大学耳鼻喉眼学报, 2021, 35(6): 108-112.
[5] 冯成敏,敬一丹,刘海,王冰. 咽喉部鳞状细胞癌细胞系[J]. 山东大学耳鼻喉眼学报, 2021, 35(6): 113-124.
[6] 刘盼,王川,赵泽祺,吴梅,徐继峰,李巍,张伟强,刘稳. 头颈部转移性透明细胞癌5例并文献复习[J]. 山东大学耳鼻喉眼学报, 2021, 35(4): 45-50.
[7] 王莹莹,周涵,董伟达,邢光前,陈智斌,张清照,张立庆. 外耳道腺样囊性癌的远处转移及预后分析[J]. 山东大学耳鼻喉眼学报, 2021, 35(1): 1-6.
[8] 谭玉芳,易天华. 鼻咽癌放疗后突发性聋18例[J]. 山东大学耳鼻喉眼学报, 2021, 35(1): 35-39.
[9] 范黎,黎越,徐细明. 鼻咽癌同步放化疗前后炎性指标变化及预测价值[J]. 山东大学耳鼻喉眼学报, 2020, 34(6): 36-41.
[10] 黄俊伟,陈学军,刘宏飞,陶冶,李祖飞,陈平,张洋. 细胞周期蛋白E2在下咽癌中的表达及其意义[J]. 山东大学耳鼻喉眼学报, 2020, 34(5): 132-137.
[11] 韩继波,邹游,杨蕊,陶泽璋. Notch受体调控上皮-间质转化对鼻咽癌细胞顺铂耐药的影响[J]. 山东大学耳鼻喉眼学报, 2020, 34(4): 105-110.
[12] 周芳茗,谢艳,刘洋蒋路云. 鼻源性头痛的研究动态分析[J]. 山东大学耳鼻喉眼学报, 2020, 34(4): 130-133.
[13] 徐进敬,胡京华,吴元庆,邓毅,喻唯唯. CO2激光显微手术在喉癌前病变和早期声门型喉癌中的应用[J]. 山东大学耳鼻喉眼学报, 2020, 34(3): 129-133.
[14] 陈慧君,宋圣花,董伟达,周涵. 术前外周血纤维蛋白原水平对喉癌预后的影响[J]. 山东大学耳鼻喉眼学报, 2020, 34(2): 110-114.
[15] 丁玉静,兰兰,王秋菊,冀飞,熊芬,谢林怡,丁海娜,夏寅,赵辉. 外伤导致听力损失的临床特点及预后[J]. 山东大学耳鼻喉眼学报, 2020, 34(1): 9-14.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] 邓基波,孙奉乾,许安廷 . 大前庭导水管综合征[J]. 山东大学耳鼻喉眼学报, 2006, 20(2): 116 -118 .
[2] 周子宁,金国威 . 喉气管狭窄的预防和治疗进展[J]. 山东大学耳鼻喉眼学报, 2006, 20(5): 462 -465 .
[3] 周斌,李滨 . 鼻内窥镜下鼻窦鼻息肉手术75例疗效观察[J]. 山东大学耳鼻喉眼学报, 2006, 20(1): 24 -26 .
[4] 徐赛男,杨雷 . 红霉素促进鼻息肉上皮细胞凋亡的实验研究[J]. 山东大学耳鼻喉眼学报, 2006, 20(1): 27 -29 .
[5] 张玉光,韩旭光,张华,王旭,徐湘辉 . 改良穿透性角膜移植术治疗真菌性角膜炎[J]. 山东大学耳鼻喉眼学报, 2006, 20(1): 94 -95 .
[6] 刘联合 . 颈深部脓肿37例[J]. 山东大学耳鼻喉眼学报, 2008, 22(2): 180 -181 .
[7] 谢治年 ,姬长友 . RNA干扰及其在喉鳞癌研究中的应用[J]. 山东大学耳鼻喉眼学报, 2008, 22(3): 200 -203 .
[8] 乔 艺,倪关森,陈文文 . 改良悬雍垂腭咽成形术联合鼻腔手术治疗阻塞性睡眠呼吸暂停综合征38例[J]. 山东大学耳鼻喉眼学报, 2008, 22(3): 206 -208 .
[9] 汪晓锋,林 昶,程金妹 . 不同龄小鼠内耳中ABAD的表达及临床意义[J]. 山东大学耳鼻喉眼学报, 2008, 22(3): 207 -211 .
[10] 凡启军,黄治物,梅 玲,肖伯奎 . 荧光定量PCR测定水杨酸钠作用后大鼠耳蜗基因的表达[J]. 山东大学耳鼻喉眼学报, 2008, 22(3): 212 -214 .
网站版权所有 © 2018 《山东大学耳鼻喉眼学报》编辑部　
地址：山东省济南市山大南路27号（250100）电话：+86-0531-88366912 E-mail: ebhxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发